Viva Biotech Holdings (VBIZF)
OTCMKTS · Delayed Price · Currency is USD
0.1850
0.00 (0.00%)
At close: Aug 4, 2025
Viva Biotech Holdings Employees
Viva Biotech Holdings had 2,063 employees as of December 31, 2024. The number of employees decreased by 14 or -0.67% compared to the previous year.
Employees
2,063
Change (1Y)
-14
Growth (1Y)
-0.67%
Revenue / Employee
$131,933
Profits / Employee
$11,110
Market Cap
440.57M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 2,063 | -14 | -0.67% |
| Dec 31, 2023 | 2,077 | -524 | -20.15% |
| Dec 31, 2022 | 2,601 | 474 | 22.28% |
| Dec 31, 2021 | 2,127 | 508 | 31.38% |
| Dec 31, 2020 | 1,619 | 888 | 121.48% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Tian'an Technology Group | 8 |
| Elite Pharmaceuticals | 68 |
| Glass House Brands | 374 |
| Northwest Biotherapeutics | 25 |
| American Oncology Network | 1,914 |
| CytoDyn | 13 |
| Silence Therapeutics | 116 |
Viva Biotech Holdings News
- 4 months ago - Viva Biotech's Wholly-Owned Subsidiary Langhua Pharmaceutical Successfully Passes U.S. FDA On-Site Inspection - PRNewsWire
- 4 months ago - Viva Biotech Announces 2024 Annual Results: Significantly Rebounding in Performance with New Stage ahead, AI Leads to a New Era of Novel Drug R&D - PRNewsWire
- 8 months ago - Viva Biotech Officially Establishes Boston Branch, Marking Another Milestone in Global Expansion - PRNewsWire
- 1 year ago - Viva Biotech Announces Its 2024 Interim Results: Significant Improvement in Net Profit Growth and Ongoing Optimization of Emerging Technology Platforms - PRNewsWire
- 1 year ago - Viva Biotech (1873.HK) Announces 2023 Annual Results: Successful Implementation of Light-asset Strategy, Achieving Solid Growth and Promising Future - PRNewsWire
- 1 year ago - Viva Biotech Secures Approximately US$ 210 Million Funding - PRNewsWire
- 2 years ago - Viva Biotech (1873.HK) Announces 2023 Interim Results: Solid Growth in Main Business, Significant Rebound in Profitability - PRNewsWire
- 2 years ago - Viva Biotech's Portfolio Company Riparian Pharmaceuticals Announces Exclusive License Agreement and Research Agreement with Pfizer for Novel Cardiovascular Programs - PRNewsWire